Get started

CGC

CGC BULLISH EMA 20 CROSSOVER IMMINENT-Earnings next weed### Investment Thesis on Canopy Growth Corporation (CGC) This is not financial advice of any kind. Do your research! 1. Overview and Rationale Canopy Growth Corporation (CGC) is one of the leading players in the cannabis industry. With the potential reclassification of cannabis by the US Federal government, CGC stands to benefit significantly from increased market access, reduced regulatory burdens, and expanded business opportunities. 2. Fundamental Analysis - **Market Position**: CGC has a strong market presence in Canada and is strategically positioned to enter the US market upon federal legalization. - **Revenue Growth**: The company has been showing steady revenue growth with expanding product lines, including recreational and medicinal cannabis, CBD products, and partnerships with beverage companies. - **Strategic Partnerships**: Canopy Growth's partnership with Constellation Brands provides a robust financial backing and enhances its product portfolio with cannabis-infused beverages. - **Potential for US Market Entry**: Reclassification by the US Federal government could open a significant revenue stream for CGC, given the size and growth potential of the US cannabis market. 3. Technical Analysis **Exponential Moving Average (EMA) Analysis** - **EMA 20 Cross Over**: The EMA 20 is on the verge of crossing above the EMA 50. This crossover is typically seen as a bullish signal, indicating a potential upward trend in the stock price. - **Historical Performance**: Previous EMA 20 crossovers have been followed by significant price increases, suggesting a reliable pattern for future predictions. **Triple Dive Pattern** - **Formation**: CGC has recently formed a triple dive pattern, characterized by three successive lows followed by a reversal. - **Implications**: This pattern often indicates a strong support level, suggesting that the stock is unlikely to fall further and may be poised for a bullish reversal. **Keltner Channels** - **Current Position**: CGC's stock price is currently at the lower band of the Keltner Channel, which often indicates that the stock is oversold. - **Potential Movement**: A move back towards the middle or upper band of the Keltner Channel would signal a potential upside, aligning with other bullish indicators. 4. Risk Factors - **Regulatory Risk**: While reclassification is a significant catalyst, it remains uncertain and dependent on political processes. - **Market Volatility**: The cannabis industry is known for its volatility, and CGC is no exception. Investors should be prepared for potential fluctuations. - **Execution Risk**: The ability of CGC to capitalize on US market opportunities will depend on effective execution of its expansion strategy. 5. Investment Strategy Given the combination of fundamental strengths and positive technical indicators, CGC appears to be a compelling investment opportunity. The potential reclassification of cannabis by the US Federal government could serve as a significant catalyst for the stock. The imminent EMA 20 crossover, triple dive pattern, and current position within the Keltner Channels all support a bullish outlook. **Recommended Action**: Initiate a position in CGC stock, with a focus on medium to long-term gains. Monitor technical indicators closely for confirmation of trends and be prepared for potential volatility. --- ### Follow-up Question How would you assess the impact of the potential reclassification of cannabis by the US Federal government on CGC's market strategy and revenue projections? "The mind adapts and converts to its own purposes the obstacle to our acting. The impediment to action advances action. What stands in the way becomes the way." — Marcus Aurelius
NASDAQ:CGCLong
by Stranglemaniac
1
CGC prepping for generous PRICE GROWTH!NASDAQ:CGC (Canopy Growth Corp) CGC is lowkey trying to cook something based on the recent price action this past 6 weeks. Net positive volume / accumulation has almost doubled this past few days, from 35M to 61m and continuing to rise. Last QTR earnings (August 9, 2023) has aided the significant price recovery - propelling earnings to green territory to 60.3% and revenues to 20%, first green output in the last 5 quarters (15 months). RR ratio on this one looks attractive. Spotted at 0.55 TAYOR. *Safeguard funds always. Factor the muted financial standing of this stock before trading.
NASDAQ:CGCLong
by JSAL
10
Biden Administration Proposes Major Shift in Cannabis PolicyThe Biden administration has taken steps to reclassify marijuana use as a less serious crime. This potential policy change, if finalized, stands to be the most substantial adjustment in federal marijuana regulations in over four decades. The U.S. Department of Justice, overseeing the Drug Enforcement Administration (DEA), has recommended reclassifying cannabis from a Schedule I drug, which denotes substances with a high potential for abuse and no accepted medical use, to a Schedule III drug. This reclassification would reflect a recognition of marijuana's lower potential for physical and psychological dependence compared to other controlled substances. Shares of cannabis companies soared in response to the news, with stocks like Tilray, Trulieve Cannabis Corp, and Green Thumb Industries experiencing surges of over 20% in late afternoon trading. This market reaction underscores the significant financial implications of potential regulatory changes in the cannabis industry. However, it's crucial to note that while the proposed reclassification may lessen the severity of penalties associated with marijuana use, it does not equate to outright legalization for recreational purposes. The shift in classification would likely result in revised sentencing guidelines and potentially open avenues for expanded medical research into cannabis-derived treatments. The proposal is now in the hands of the White House Office of Management and Budget for review and the finalization of the rule-making process. Despite the positive reception from cannabis advocates and investors, the DEA has yet to officially comment on the recommendation. The Biden administration's move reflects a growing shift in public attitudes towards marijuana, with an increasing number of states legalizing its recreational or medicinal use. By reevaluating federal cannabis policies, the administration aims to align with evolving societal norms and address longstanding disparities in drug enforcement practices. Critics argue that the proposed reclassification does not go far enough in addressing broader issues related to drug policy reform, such as racial disparities in marijuana-related arrests and convictions. Nevertheless, proponents view it as a crucial step towards a more rational and equitable approach to cannabis regulation. Technical Outlook Canopy Growth Corporation ( NASDAQ:CGC ) stock is up 62% as a result of the Biden Administration policy on cannabis taking the stock to an overbought region with a Relative Strength Index (RSI) of 73. Further accentuating to the bullish trend is the long "Bullish Harami" candle stick pattern depicted on the daily price chart.
NASDAQ:CGCLong
by DEXWireNews
1
CGC trade from bounce at fib level LONGCGC fell in a standard Fibonacci retracement of 3 week trend up from Mid-March. News of an application to issue a new class of shares may as well be considered a dilution of current shareholders. CGC is 5 days away from National MJ Day of the 20th. I expect a further pullback into the 0.618 level given the fundamental news but CGC could rally on trader interest regarding the notable day. My trade plan is to buy a pullback if and whne it finds support at 6.15 and then enter long seeking the target of 7.95 which would be a Fib 0.5 retracement of the trend down. I will look at other MJ stocks as well.
NASDAQ:CGCLong
by AwesomeAvani
4
YCBD- another marijuana pneey stock lights it up LONGThe idea is on the 15 minute chart here- See also ideas for OBI, ACB, TLRY, and CGC Germany also is pushing full legalization. A new day is dawning? Several states are working on releasing minor offenders ( clemency and pardoning). YCBD is risky but the potential rewards are great. As for me, a fair position with a stop loss of 10% targets of 50%, 100% and 200%. I am in no hurry and will accept the cup and handle as being over a relatively short period of time and so not necessarily highly reliable. Nevertheless, i will chase some of the hottest things around- penny and low priced marijuana stocks. (Very) HOT until they are not.
AMEX:YCBDLong
by AwesomeAvani
Germany Greenlights Recreational Cannabis, But With CaveatsGermany's Federal Council has given the green light to a bill legalizing recreational cannabis for personal use, marking a significant shift in drug policy within the European nation. Despite facing criticism and opposition, the legislation, passed by the Bundestag earlier, paves the way for individuals to possess and cultivate cannabis starting April 1, albeit with certain restrictions. While the approval signals a milestone in Germany's approach to cannabis regulation, the journey towards legalization has been far from smooth. Several federal states voiced dissent, with only a handful advocating for a renegotiation of the law. Ultimately, the absence of a majority for an appeal to the mediation committee cleared the path for implementation. Health Minister Karl Lauterbach, a key proponent of the law, emphasized its potential to safeguard the younger generation by curbing consumption and dismantling the black market. The legislation, coupled with increased funding for addiction prevention measures, underscores the government's commitment to public health and education. Under the new law, adults aged 18 and over will be permitted to possess up to 25 grams of cannabis and cultivate up to three plants for personal use. However, strict regulations prohibit smoking in public spaces, including schools and sports facilities, ensuring responsible consumption. Moreover, the legislation introduces the concept of cannabis social clubs, enabling up to 500 members to collectively cultivate and exchange cannabis within defined limits. This initiative aims to foster community engagement while providing a framework for responsible cannabis use. Looking ahead, the government plans to evaluate the law's impact on youth protection within 18 months of implementation. Additionally, discussions are underway to explore the controlled sale of cannabis through pilot programs, mirroring successful initiatives in neighboring countries like Switzerland and the Netherlands.
NASDAQ:CGC
by DEXWireNews
Canopy Growth Poised for German Cannabis Market BoomIn a groundbreaking development for the global cannabis industry, Germany's decision to legalize cannabis marks a significant turning point, paving the way for increased access and growth opportunities. Canopy Growth Corporation (Nasdaq: NASDAQ:CGC ), a leading player in the cannabis sector, stands poised to capitalize on this historic moment, positioning itself for accelerated expansion and market dominance. Germany's Cannabis Legalization: A Game-Changer The German government's approval to recognize cannabis as a non-narcotic represents a monumental shift in policy, signaling broader acceptance and normalization of cannabis consumption. Effective April 1, 2024, adult consumers in Germany will be able to legally access cannabis products without fear of prosecution, a move applauded by industry stakeholders and advocates alike. Canopy Growth's Strategic Advantage For Canopy Growth ( NASDAQ:CGC ), the legalization of cannabis in Germany presents a unique opportunity to bolster its commercial presence and solidify its position as a key player in the German market. Leveraging its diversified portfolio, including the renowned Storz & Bickel vaporizer brand and Canopy Medical's medical cannabis offerings, the company is poised to capture significant market share and drive revenue growth. Storz & Bickel: Leading the Vaporizer Revolution With the legalization of recreational cannabis, Storz & Bickel stands to benefit from increased demand for its premium vaporizer products. As one of the most respected brands in the industry, Storz & Bickel is well-positioned to capitalize on the burgeoning German market, offering consumers the highest quality vaporization devices backed by years of expertise and innovation. Canopy Medical: Meeting Patient Needs For Canopy Medical, Germany's reclassification of cannabis as a non-narcotic represents a major breakthrough in patient access to medical cannabis. With the potential for more patients to explore cannabis as a treatment option, Canopy Growth is committed to delivering high-quality products that meet the diverse needs of patients while driving awareness and education within the medical community. Driving Awareness and Collaboration Beyond product offerings, Canopy Growth ( NASDAQ:CGC ) is dedicated to driving awareness and fostering collaboration within the medical community through educational initiatives and partnerships. By engaging with physicians and patients, the company aims to promote the therapeutic benefits of cannabis and establish itself as a trusted provider of medical cannabis solutions.
NASDAQ:CGCLong
by DEXWireNews
"Canopy Growth Corporation Faces Critical Support Test"Canopy Growth Corporation: Navigating Market Challenges and Strategic Goals Canopy Growth Corporation, a prominent player in the cannabis industry, has been a focal point for investors seeking exposure to the rapidly expanding market for legal marijuana products. As one of the largest cannabis producers globally, Canopy Growth has garnered attention for its ambitious goals and strategic initiatives aimed at capitalizing on the burgeoning demand for cannabis-related products. Founded in 2013, Canopy Growth has quickly risen to prominence, establishing itself as a leader in the cannabis industry through a combination of strategic acquisitions, innovative product development, and global expansion efforts. The company's primary focus is on cultivating, producing, and distributing a diverse range of cannabis products, including dried flower, oils, edibles, and beverages. In recent years, Canopy Growth has achieved several notable milestones, reflecting its commitment to growth and innovation. These achievements include expanding its production capacity, securing distribution agreements with leading retailers, and launching new product lines to meet evolving consumer preferences. However, despite its successes, Canopy Growth has faced challenges in navigating the volatile cannabis market, particularly in the wake of a prolonged distribution bear market that has persisted for the past five years. The company's stock price has experienced significant fluctuations, reflecting the uncertainty surrounding regulatory environments, shifting consumer trends, and competitive pressures within the industry. Recently, Canopy Growth's stock price experienced a sharp retracement, testing critical support levels around $18 per share. With the stock now poised to retest its previous lows at $4 per share, investors are closely monitoring the situation for signs of a potential breakout or breakdown. The recent spike in volume accompanying the bounce from support suggests heightened volatility and the potential for significant price movements in the near term. Bears may attempt to crack support levels, with the possibility of a further downward spiral if volume flows through aggressively enough. In such a scenario, the stock could potentially retest long-term downward support levels around $2 per share. On the other hand, if Canopy Growth manages to break out of its current pennant pattern, investors may view this as an opportunity to enter a position targeting the top of long-term resistance levels. A successful breakout could pave the way for renewed upward momentum, offering potential upside for savvy traders. In conclusion, Canopy Growth Corporation continues to navigate challenges in the cannabis market while pursuing strategic goals aimed at driving long-term growth and profitability. As the company grapples with support levels and potential breakout opportunities, investors should remain vigilant and adaptable, prepared to capitalize on emerging trends and developments in this dynamic industry.
NASDAQ:CGC
by UnknownUnicorn2319099
3
CGC (cannabis stocks 🔥) "Looks bearish ATH"cannabis stocks in 2024 have been showing remarkable potential and resilience, reflecting a burgeoning industry with promising prospects. The landscape continues to evolve, presenting exciting opportunities for growth and innovation. With increasing legalization, expanding markets, and advancing technology, the future looks incredibly bright for those investing in cannabis. It's a dynamic sector with significant room for growth, making it an inspiring space to be a part of.
NASDAQ:CGCLong
by TrojanBible
CGC 🆕Investing in cannabis stocks has been a rollercoaster ride, with fluctuating values due to legal, regulatory, and market factors. Despite volatility, the future looks promising as legalization continues in various regions. Motivation lies in the potential growth as the industry matures and gains wider acceptance, leading to increased market opportunities and potential profits for savvy investors. Understanding the landscape, staying informed about legislative changes, and diversifying your portfolio can help navigate the uncertainties and maximize the potential of cannabis stocks in the long run
NASDAQ:CGCLong
by TrojanBible
CGC (Cannabis stock )Investing in cannabis stocks has been a rollercoaster ride, with fluctuating values due to legal, regulatory, and market factors. Despite volatility, the future looks promising as legalization continues in various regions. Motivation lies in the potential growth as the industry matures and gains wider acceptance, leading to increased market opportunities and potential profits for savvy investors. Understanding the landscape, staying informed about legislative changes, and diversifying your portfolio can help navigate the uncertainties and maximize the potential of cannabis stocks in the long run
NASDAQ:CGCLong
by TrojanBible
Canopy Growth Announces Effective Date of Share Consolidation Canopy Growth Corporation (NASDAQ:CGC) announced on Wednesday that its board of directors has approved the consolidation of its issued and outstanding common shares based on one post-consolidation common share for every ten pre-consolidation common shares. The consolidation, which was previously approved by shareholders at their annual general and special meeting on Sept. 25, is being implemented to ensure that the company continues to comply with the listing requirements of the Nasdaq Global Select Market, the Ontario-based company said in a press release. Now, the consolidation is subject to approval by the Toronto Stock Exchange (TSX) and is expected to become effective on Friday, Dec.15, with the post-consolidation common shares commencing trading on the TSX and the Nasdaq at market open on Wednesday, Dec. 20, subject to final confirmation from the TSX and the Nasdaq. Technical Analysis NASDAQ:CGC stock may face resistance at the 50-day moving average of $0.6092 and support at the recent low of $0.545. Waiting for a confirmation of a trend reversal before entering or exiting the market would be very crucial.
NASDAQ:CGCLong
by DEXWireNews
Psychemedics PMD micro-cap Due For Bullish Reversal Cycle 5% Dividend Yield, with 100% upside Share Potential The world’s largest provider of hair testing for drugs of abuse announced financial results for the first quarter ended March 31, 2023 And the declaration of a cash dividend of $0.07 per share to be paid on June 8, 2023, to shareholders of record as of May 25, 2023 The Company’s revenue for the quarter ended March 31, 2023, was $5.9 million versus $6.5 million for the quarter ended March 31, 2022, a decrease of 10%. Net loss for the quarter ended March 31, 2023, was $(384,000) or $(0.07) per diluted share, versus net income of $39,000 or $0.01 per diluted share, for the comparable period last year. Psychemedics Corporation is a United States corporation which provides patented, FDA-cleared, CAP certified clinical laboratory services for the detection of drugs of abuse. The company's corporate headquarters are located in Acton, Massachusetts and its laboratory operations are located in Culver City, California. Wikipedia
NASDAQ:PMDLong
by noam_chom